



HAL
open science

Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method

Blandine Truffault, David Bourhis, Anne Chaput, Jérémie Calais, Philippe Robin, Romain Le Pennec, François Lucia, Jean-Christophe Leclère, Dorothy Gujral, Pierre Vera, et al.

► To cite this version:

Blandine Truffault, David Bourhis, Anne Chaput, Jérémie Calais, Philippe Robin, et al.. Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. *Frontiers in Medicine*, 2020, 7, pp.218. 10.3389/fmed.2020.00218 . hal-02922556

HAL Id: hal-02922556

<https://hal.science/hal-02922556>

Submitted on 22 Dec 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method

Blandine Truffault¹, David Bourhis^{1,2}, Anne Chaput¹, Jeremie Calais^{3,4}, Philippe Robin^{1,2}, Romain Le Pennec¹, François Lucia⁵, Jean-Christophe Leclère⁶, Dorothy M. Gujral^{7,8}, Pierre Vera⁴, Pierre-Yves Salaün^{1,2}, Ulrike Schick⁵ and Ronan Abgral^{1,2*}

¹ Department of Nuclear Medicine, Brest University Hospital, Brest, France, ² European University of Brittany, Brest, France, ³ Department of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States, ⁴ Department of Nuclear Medicine and Radiology, Henri Becquerel Center, Quantif (LITIS EA 4108 – FR CNRS 3638), Rouen University Hospital, Rouen, France, ⁵ Department of Radiotherapy, Brest University Hospital, Brest, France, ⁶ Department of Oto-rhino-laryngology, Brest University Hospital, Brest, France, ⁷ Clinical Oncology Department, Imperial College Healthcare NHS Trust, Charing Cross Hospital, Hammersmith, London, United Kingdom, ⁸ Department of Cancer and Surgery, Imperial College London, London, United Kingdom

OPEN ACCESS

Edited by:

Francesco Cicone,
University of Catanzaro, Italy

Reviewed by:

Maria Picchio,
San Raffaele Hospital (IRCCS), Italy
Egesta Lopci,
Milan University, Italy

*Correspondence:

Ronan Abgral
ronan.abgral@chu-brest.fr

Specialty section:

This article was submitted to
Nuclear Medicine,
a section of the journal
Frontiers in Medicine

Received: 31 January 2020

Accepted: 30 April 2020

Published: 04 June 2020

Citation:

Truffault B, Bourhis D, Chaput A, Calais J, Robin P, Le Pennec R, Lucia F, Leclère J-C, Gujral DM, Vera P, Salaün P-Y, Schick U and Abgral R (2020) Correlation Between FDG Hotspots on Pre-radiotherapy PET/CT and Areas of HNSCC Local Relapse: Impact of Treatment Position and Images Registration Method. *Front. Med.* 7:218. doi: 10.3389/fmed.2020.00218

Aim: Several series have already demonstrated that intratumoral subvolumes with high tracer avidity (hotspots) in 18F-fluorodesoxyglucose positron-emission tomography (FDG-PET/CT) are preferential sites of local recurrence (LR) in various solid cancers after radiotherapy (RT), becoming potential targets for dose escalation. However, studies conducted on head and neck squamous cell carcinoma (HNSCC) found only a moderate overlap between pre- and post-treatment subvolumes. A limitation of these studies was that scans were not performed in RT treatment position (TP) and were coregistered using a rigid registration (RR) method. We sought to study (i) the influence of FDG-PET/CT acquisition in TP and (ii) the impact of using an elastic registration (ER) method to improve the localization of hotspots in HNSCC.

Methods: Consecutive patients with HNSCC treated by RT between March 2015 and September 2017 who underwent FDG-PET/CT in TP at initial staging (PET_A) and during follow-up (PET_R) were prospectively included. We utilized a control group scanned in non treatment position (NTP) from our previous retrospective study. Scans were registered with both RR and ER methods. Various sub-volumes (A_x; x = 30, 40, 50, 60, 70, 80, and 90% SUVmax) within the initial tumor and in the subsequent LR (R_x; x = 40 and 70% SUVmax) were overlaid on the initial PET/CT for comparison [Dice, Jaccard, overlap fraction = OF, common volume/baseline volume = A_xnR_x/A_x, common volume/recurrent volume = A_xnR_x/R_x].

Results: Of 199 patients included, 43 (21.6%) had LR (TP = 15; NTP = 28). The overlap between A₃₀, A₄₀, and A₅₀ sub-volumes on PET_A and the whole metabolic volume of recurrence R₄₀ and R₇₀ on PET_R showed moderate to good agreements (0.41–0.64) with OF and A_xnR_x/R_x index, regardless of registration method or patient

position. Comparison of registration method demonstrated OF and $A_x n R_x / R_x$ indices ($x = 30\%$ to 50% SUVmax) were significantly higher with ER vs. RR in NTP ($p < 0.03$), but not in TP. For patient position, the OF and $A_x n R_x / R_x$ indices were higher in TP than in NTP when RR was used with a trend toward significance, particularly for $x=40\%$ SUVmax (0.50 ± 0.22 vs. 0.31 ± 0.13 , $p = 0.094$).

Conclusion: Our study suggested that PET/CT acquired in TP improves results in the localization of FDG hotspots in HNSCC. If TP is not possible, using an ER method is significantly more accurate than RR for overlap estimation.

Keywords: FDG-PET/CT hotspots, local relapse, HNSCC, images registration, radiotherapy treatment position

INTRODUCTION

Head and neck squamous cell cancer carcinomas (HNSCC) are the sixth most common cancer (1, 2) with around 800,000 new cases worldwide in 2015. These tumors have a poor prognosis, with a 5-year survival rate $< 50\%$ (3), particularly because two thirds of patients are unfortunately diagnosed at advanced stage. In addition to surgery, concurrent chemo-radiotherapy is a standard of care in the curative-intent management of locally advanced tumors (4, 5). However, despite improvements in treatment modalities, locoregional failure rates remain high (4, 6).

Several studies have suggested that local recurrence (LR) of HNSCC treated with radiotherapy (RT) occurs mainly within the planning target volume (PTV) regardless of radiotherapy technique, suggesting that the radiation dose delivered may be insufficient for local tumor control (7). RT dose escalation is often limited by the tolerance of surrounding tissues and the associated risk of radiation-induced toxicities (8–10). Therefore, the ability to accurately define and irradiate areas at high risk of recurrence could be useful to guide a boost protocol with the use of modern techniques such as intensity modulated radiotherapy (IMRT) and stereotactic radiotherapy (11, 12).

The usefulness of 18Fluorodesoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for initial staging, therapeutic assessment and recurrence diagnosis in HNSCC is now well established (13–15). It is also increasingly considered a useful tool in RT to optimize target volume contouring. Indeed, it allows the delineation of target volume boundaries more precisely, with reduction in inter- and intra-observer reproducibility compared to CT (16–19). In addition, FDG-PET/CT is currently being investigated as a tool to guide radiotherapy dose escalation in order to decrease toxicities and improve tumor control (20). One of the most important studies in this context is the ongoing multicentric trial ARTFORCE (NCT01504815), which compares a standard dose of 70 Gy with an FDG-PET/CT-based simultaneous integrated boost to areas of high FDG uptake (hotspots) up to a maximum dose of 84 Gy (21).

Recent studies have reported a high risk of LR within FDG hotspots identified on pre-RT PET/CT in lung (22–25), rectal (26), and esophageal malignancies (27). Nevertheless, two previous studies conducted on HNSCC failed to confirm good correlation between areas of high FDG uptake and preferential

sites of local recurrence (28, 29). Indeed, we recently found only a modest overlap index (< 0.6) between pre- and post-treatment subvolumes in 19 recurrent lesions (28). One possible explanation lies in the lack of reproducibility of the patients positioning between the two scans. Moreover, weight loss and post-therapeutic tissues distortion in HNSCC could also affect anatomical landmarks, making the registration process with a rigid approach more difficult.

Our main objective was to prospectively determine if PET-CT acquisition in the same RT position and image co-registration with an elastic registration method could improve the overlap between FDG hotspots and HNSCC local relapse subvolumes. Therefore, the study aimed to investigate whether a difference existed between (i) RR and ER registration methods and (ii) TP versus NTP patient positioning for PET-CT acquisition. We also sought to define the optimal SUVmax threshold to identify the lowest volume on the initial PET that could be used as a reduced target volume of RT.

A secondary objective of this study was to confirm the prognostic value of initial metabolic tumor burden (metabolic tumor volume = MTV and total lesion glycolysis = TLG) in patients with HNSCC.

MATERIALS AND METHODS

Population

Consecutive patients with histologically proven HNSCC treated with RT with or without concomitant systemic treatment referred between March 2015 and September 2017 to our department for FDG-PET/CT were prospectively enrolled in the current study. All patients had FDG-PET/CT before and after treatment in TP. A control group scanned in NTP from our previously published retrospective series was used for comparison (28).

Treatment Modalities

All patients were treated with RT \pm chemotherapy according to international guidelines (30). External RT was delivered using volumetric modulated arc therapy (VMAT) on a Truebeam STx accelerator (Varian[®], Palo Alto, USA). The gross tumor volume (GTV) was delineated on a planning CT scan after combining the information provided by endoscopy, contrast-enhanced diagnostic CT or MRI. The dose to the GTV

was 70Gy (2Gy/fraction/day, 5 sessions/week) over 7 weeks +/- concomitant systemic treatment: Cetuximab, Cisplatin or Carboplatin.

Follow-Up

Clinical follow-up was performed as recommended by the National Comprehensive Cancer Network (30). Patients with persistent disease on FDG-PET/CT 3 months after RT completion, and those who, after initial complete response, relapsed within the radiation field during follow-up were pooled together to comprise the LR group. Histological evidence was highly recommended; otherwise evidence of progression on imaging was used to define LR.

The following clinical characteristics were obtained for each patient and considered as variables in univariate analysis: age, sex, tumor location, AJCC stage, systemic treatment modality, RT dose and RT duration.

FDG-PET/CT Imaging

The first FDG-PET/CT (PET_A) was performed for initial staging. The post-therapeutic PET_R was defined as either the PET performed at the time of the first evaluation (3 months) in patients showing persistent/progressive disease, or the first PET performed during follow-up (suspected recurrence or systematic surveillance) that demonstrated LR. All indications for FDG PET/CT were reviewed according to guidelines (15, 30) by a multidisciplinary team.

All FDG-PET/CT data were acquired on a Biograph-mCT™ system (Siemens®, Erlangen, Germany) in the same institution. The patients were required to fast for at least 6h before imaging. Scans were performed 60 min after injection of ~3–4 MBq/kg of FDG (IBA molecular imaging®, Saclay, France). From March 2015, patients were scanned according to their compliance in TP, supine on a rigid board, neck maintained in a semi-rigid headrest. As previously mentioned, patients from our control group (28) were supine without rigid board or headrest (NTP).

PET data were acquired using a whole-body protocol (2 min per step, 200x200 matrix) and reconstructed using an ordered subsets expectation-maximization (OSEM) algorithm (TrueX™=PSF (point spread function) + time of flight (TOF) OSEM-3D with 4 x 4 x 2 mm voxels. Data were corrected for random coincidences, scatter and attenuation using the CT scan. PET images were smoothed with a Gaussian filter (full-width at half-maximum = 2 mm).

CT data were acquired in the cranio-caudal direction using a whole body protocol. Intravenous iodine contrast agent (1.5 mL/kg) was used for the CT scan unless contraindicated. The CT consisted of a 64-slice multidetector-row spiral scanner with a transverse field of view of 700 mm. The CT parameters were a collimation of 16 x 1.2 mm, pitch = 1, tube voltage and exposure were automatically regulated (CarekV®, CareDose 4D®) with 120 kV and 80 QrefmAs as basis parameters and CT iterative reconstruction was used (SAFIRE®, strength 5).

The study was approved by our institutional ethics committee (number 2017.CE25). All patients gave written informed consent.

FDG-PET/CT Analysis

All scans were analyzed by the same nuclear medicine physician (BT). The registration and overlap comparisons were then performed using the MIM™ software (MIM™ Software Inc., Cleveland, USA). For each patient, two registration methods (RR and ER) were studied.

For the RR method, the CT of PET_A (CT_A) was registered with CT of PET_R (CT_R), focusing on the tumor area. Regions of interest were identified and outlined on the CT, using PET images as reference. Manual adjustment was not allowed. The transformations derived from the CT registration process were then reported on PET_A images.

The ER method was performed by the VoxAlign® Engine algorithm, a constrained intensity based, free-form registration (31). A rigid registration between CT_A and CT_R was first performed, followed by ER. The deformable registration matrix was saved, and applied to PET_A. These deformations led to an elastic registered CT and PET.

Seven volumes of interest (VOIs) on PET_A and 2 VOIs on PET_R (metabolic active residual disease or relapse) were respectively defined. On PET_A, baseline sub-volumes were delineated using a relative threshold method (A_x with x = 30, 40, 50, 60, 70, 80, and 90% of SUVmax). On PET_R, thresholds at x = 40 and 70% of SUVmax were respectively used to delineate R₄₀ and R₇₀ recurrent sub-volumes. Baseline sub-volumes A_x were reported on PET_R, and recurrence sub-volumes R_x were reported on PET_A, to quantify their respective overlaps (Figure 1).

The following quantitative parameters were also collected on PET_A for the prognosis analysis: SUVmax, SUVmean, MTV, and TLG (TLG = SUVmean × MTV).

Overlap Estimation

All potential overlaps between baseline tumor sub-volumes (A₃₀ to A₉₀) vs. relapse (R₄₀ and R₇₀) sub-volumes were investigated using five indices [Dice, Jaccard, overlap fraction (OF), common volume divided by the initial volume (A_xnR_x/A_x) and common volume divided by the compared volume (A_xnR_x/R_x)], as recommended by Calais et al. (22, 27) and as applied in our previous study (28).

Index values for each parameter vary between 0 if the volumes are completely disjointed and 1 if the volumes match perfectly in size, shape and location.

This overlap analysis was conducted on 4 subgroups: NTP-RR, NTP-ER, TP-RR, and TP-ER.

A schematic example of the interpretation of overlap indices is represented in Figure 2.

Statistics

The quality of overlap was assessed using Cohen k-test for agreement between investigators as follows: 0–0.2, poor agreement; 0.21–0.40, fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, good agreement; and 0.81–1.00, very good agreement (32). Comparison of mean overlap in different subgroups was performed using the Wilcoxon or Mann-Whitney *U*-tests as appropriate. The statistical associations between FDG-PET/CT and




FIGURE 1 | Typical A_{70} and R_{40} sub-volumes overlap estimation after co-registration and reports. Use with permission of Calais et al. (27).




FIGURE 2 | Study flow for scenario of PET_A and PET_R sub-volume comparisons. Indices of common volume ($A \cap R$) with A referring to baseline PET and R to PET at recurrence. Use with permission of Calais et al. (27).

clinical parameters were tested using a repeated measures analysis of variances (ANOVA) and the chi-2 squared test. A $p < 0.05$ was considered statistically significant. All analyses were performed using XLSTAT (Addinsoft®, Paris, France).

RESULTS


Patients Characteristics

The final cohort included 199 patients (142M/57F). Characteristics of patients are reported in **Table 1**.

TABLE 1 | Characteristics of the 199 patients included in the study.

	TOTAL (n = 199)	CR (n = 120)	DR (n = 36)	LR (n = 43)
Age, yo ± SD	62.5 ± 10.2	61.3 ± 8.9	64.0 ± 10.2	64.7 ± 12.7
Gender, n (%)				
Male	142(71.4)	85(70.8)	26(72.2)	31(72.1)
Female	57(28.6)	35(29.2)	10(27.8)	12(27.9)
Tumor location, n (%)				
Rhynchopharynx	7(3.5)	5(4.2)	1(2.8)*	1(2.3)*
Oropharynx	124(62.3)	70(58.3)	26(72.2)*	28(65.1)*
Hypopharynx	24(12.1)	14(11.7)	5(13.9)*	5(11.6)*
Larynx	31(15.6)	26(21.7)	3(8.3)*	2(4.7)*
Oral cavity	13(6.5)	5(4.2)	1(2.8)*	7(16.3)*
AJCC stage, n (%)				
I	5(2.5)	5(4.2)	0*	0*
II	16(8.0)	14(11.7)	0*	2(4.6)*
III	40(20.1)	28(23.3)	5(13.9)*	7(16.3)*
IV	138(69.3)	73(60.8)	31(86.1)*	34(79.1)*
RT Duration, (days ± SD)	54.8 ± 9.1	53.4 ± 9.4	56.7 ± 7.5	57.3 ± 8.5
RT Dose, (Gy ± SD)	70.0 ± 1.1	70.0 ± 0.5	70.3 ± 1.2	69.9 ± 1.8
Treatment, n (%)				
CRT	137(68.9)	85(20.8)	26(72.2)	26 (60.5)
Single RT	56(28.1)	31(25.8)	8(22.2)	17(39.5)

CR, Complete response; DR, Distant relapse; LR, Local relapse; SD, Standard deviation; CRT, Chemo-radiotherapy; *Significantly different from CR.



Of these, 137 (68.8%) received concomitant systemic treatment: Cetuximab (20/199), Cisplatin or Carboplatin ± 5-FU (117/199).

The mean ± SD time of follow-up of the population was 18.7 ± 11.3 months. At last follow-up, 120 (60.3%) with initial complete response remained free of disease (CR) and 43 (21.6%) experienced local relapse (LR). Twenty-nine LR were identified on imaging and confirmed pathologically. Fourteen LR were considered as such based on evidence of local and metastatic progression disease on any imaging procedure or on clinical examination. Thirty-six patients (18.1%) showed distant dissemination (nodal or metastatic) without LR (**Figure 3**).

PET/CT Parameters

Fifteen patients with LR were scanned in TP and 28 in NTP.

The initial PET/CT parameters are summarized in **Table 2**. The mean ± SD initial MTV was 7.7 ± 7.8 cc in the entire cohort and 9.1 ± 7.2 cc in patients with LR, whereas mean ± SD initial TLG was 90.6 ± 101.8 g and 105.9 ± 80.6 g, respectively.

Overlap Comparison

A total of 6,020 overlap indices were obtained, i.e., 140 potential overlaps between the baseline PET_A VOIs and relapse PET_R VOIs in the 43 patients who had LR and using the 2 registration methods (387 VOIs on 86 PET/CT). Two typical examples are shown in **Figure 4**. Mean overlap index values are reported in **Table 3**.

A_X vs. R₄₀ Comparisons

None of the indices showed good or very good agreement. The OF(A_XnR₄₀) index showed moderate agreement (0.42–0.56) for SUVmax thresholds of 30–40% in TP-RR, TP-ER, and NTP-ER subgroups. The OF(A₅₀nR₄₀) index showed moderate agreement (0.43) in NTP-ER subgroup. The A₃₀nR₄₀/R₄₀ index showed moderate agreement (0.47–0.50) in TP-RR, TP-ER, and NTP-ER subgroups.

The Dice, Jaccard and A_XnR₄₀/A_X indices showed poor to fair agreement.

A_X vs. R₇₀ Comparisons

None of the indices showed very good agreement. The OF(A_XnR₇₀) and A_XnR₇₀/R₇₀ indices showed moderate to good agreement (0.50–0.64) for SUVmax thresholds of 30–40% in the TP-RR, TP-ER and NTP-ER subgroups. The OF(A₅₀nR₇₀) index showed moderate agreement (0.41) in the NTP-ER subgroup.

The Dice, Jaccard and A_XnR₇₀/A_X indices were very low, mostly below 0.20, irrespective of the thresholds used on PET_A.

TP vs. NTP

With RR method, the OF(A_XnR₇₀), A_XnR₄₀/R₄₀, and A_XnR₇₀/R₇₀ indices for SUVmax thresholds of 30–40% were higher in TP subgroup than in the NTP subgroup with a trend toward significance. For example, the OF(A₃₀nR₇₀) and A₃₀nR₇₀/R₇₀ indices were higher in the TP subgroup (0.59 ± 0.22) than in the NTP (0.38 ± 0.14) subgroup ($p = 0.10$); and OF(A₄₀nR₇₀) and A₄₀nR₇₀/R₇₀ were higher in the TP subgroup (0.50 ± 0.22) than in the NTP (0.31 ± 0.13) subgroup ($p = 0.094$).

With ER method, there was no significant difference between TP and NTP subgroups with the aboved-mentioned best agreement (moderate to good) of OF(A_XnR₄₀), A_XnR₄₀/R₄₀, and A_XnR₇₀/R₇₀ indices.

Elastic vs. Rigid Registration Method

In the NTP subgroup, the OF(A_XnR₄₀) and OF(A_XnR₇₀) indices for SUVmax thresholds of 30–50% were significantly higher with ER than those obtained using the RR method ($p < 0.03$). The A_XnR₇₀/R₇₀ index values for SUVmax thresholds of 30–40% were

TABLE 2 | Metabolic parameters on baseline PET/CT.

	TOTAL (n = 199)	CR (n = 120)	DR (n = 36)	LR (n = 43)	GR (n = 79)
SUVmax	20.0 ± 9.6	19.2 ± 9.5	20.1 ± 6.1	21.2 ± 8.2	20.7 ± 7.3
SUVmean	12.0 ± 5.6	11.3 ± 5.7	12.3 ± 3.8	12.5 ± 4.8	12.4 ± 4.3
MTV (cc)	7.7 ± 7.8	6.4 ± 7.1	9.8 ± 8.4*	9.1 ± 7.2*	9.4 ± 7.7*
TLG (g)	90.6 ± 101.8	75.2 ± 98.4	120.7 ± 111.4*	105.9 ± 80.6*	112.7 ± 95.5*

*Significantly different from CR. MTV = A₄₀.




FIGURE 4 | Histogram of the mean values of OF and A_{xn}R_x/R_x index for various SUVmax thresholds to delineate the volumes on PET_A (baseline) and PET_R at relapse in the 4 subgroups.

significantly higher with ER vs. RR method ($p = 0.028$). A typical example is shown in **Figure 5**.

In the TP subgroup, there was no significant difference between the RR and ER methods neither with the aboved-mentioned best agreement (moderate to good) of the OF(A_{Xn}R_X), A_{Xn}R₄₀/R₄₀ and A_{Xn}R₇₀/R₇₀ indices (**Figure 6**), nor regarding the lowest. There was only one case where the overlaps increased by a factor 3 (**Figure 7**).

Univariate Analysis

Gender, RT dose, RT duration, use of chemotherapy, baseline SUVmax and SUVmean were not statistically different between patients with complete response (CR), distant relapse (DR) or local relapse (LR). However, patients with CR were significantly younger ($p = 0.021$), and more often presented with early stage disease ($p = 0.003$), and laryngeal cancer (larynx, $p = 0.027$).

The mean ± SD MTV on baseline PET was significantly lower in the controlled patients (6.4 ± 7.1 cc) than all relapsed patients (sum of DR+LR) (9.4 ± 7.7 cc, $p = 0.006$), DR patients (9.8 ± 8.4 cc, $p = 0.031$), and LR patients (9.1 ± 7.2 cc, $p = 0.041$). The mean ± SD TLG on baseline PET was significantly lower in controlled patients (75.2 ± 98.4 g) than all relapsed patients (112.7 ± 95.5 g, $p = 0.008$) DR patients (120.7 ± 111.4 g, $p = 0.032$), and LR patients (105.9 ± 80.6 g, $p = 0.046$),

DISCUSSION

The rationale for applying the “hotspot” localization concept to HNSCC relies on the overlap of the recurrence sites with the pre-RT biological target volume (BTV). Indeed, Soto et al. reported that LR was included in the pre-treatment FDG BTV in 8/9 patients after RT (33). Based on these findings, recent articles have suggested the use of biological and functional parameters in FDG-PET/CT to identify the radioresistant tumor area (14, 34). Thereby, Jeong and al. suggested that FDG-avid tumors require at least 10–30% higher dose than non-FDG avid tumors (14).

Whilst studies on lung (22–25), rectal (26), and esophageal (27) cancers have shown good to excellent agreements between intra-tumoral FDG hotspots and areas of local recurrence, disappointing results have been obtained in series conducted on HNSCC. Indeed, Chaput et al. reported a moderate correlation between volumes identified on initial PET_A and relapse PET_R. The authors demonstrated OF(A_{Xn}R₄₀) and A_{Xn}R₄₀/R₄₀ indices showed a moderate agreement (0.52–0.43) for SUVmax thresholds of 30–50%. Moreover, moderate agreement values (0.54–0.45) of OF(A_{Xn}R₇₀) and A_{Xn}R₇₀/R₇₀ indices were obtained for baseline SUVmax thresholds between 30 and 40% (28). Using a similar PET procedure (no treatment position, rigid registration), Legot et al. reported comparable results in 38 patients: the OF(A_{Xn}R₄₀) ranged between 0.35 and 0.55 for overlaps between R₄₀ and A₃₀, A₄₀, A₅₀, and A₆₀,

TABLE 3 | Mean values of overlap indices for various SUVmax thresholds to delineate volumes on PET_A baseline (A_X) and PET_R at relapse (R₄₀ and R₇₀).

	R₄₀							R₇₀						
	A₃₀	A₄₀	A₅₀	A₆₀	A₇₀	A₈₀	A₉₀	A₃₀	A₄₀	A₅₀	A₆₀	A₇₀	A₈₀	A₉₀
DICE														
<i>RR TP</i>	0.25	0.24	0.22	0.20	0.15	0.07	0.03	0.08	0.09	0.10	0.10	0.10	0.08	0.05
<i>ER TP</i>	0.25	0.25	0.22	0.18	0.13	0.06	0.01	0.06	0.07	0.08	0.09	0.08	0.06	0.02
<i>RR NTP</i>	0.22	0.21	0.19	0.15	0.10	0.05	0.02	0.06	0.06	0.07	0.06	0.06	0.04	0.02
<i>ER NTP</i>	0.32	0.30	0.26	0.19	0.13	0.06	0.02	0.10	0.11	0.12	0.12	0.10	0.07	0.02
Jacquard														
<i>RR TP</i>	0.15	0.15	0.14	0.12	0.09	0.04	0.02	0.05	0.05	0.06	0.06	0.05	0.05	0.03
<i>ER TP</i>	0.15	0.15	0.13	0.11	0.08	0.03	0.01	0.03	0.04	0.04	0.05	0.04	0.03	0.01
<i>RR NTP</i>	0.13	0.13	0.11	0.09	0.06	0.03	0.01	0.03	0.03	0.04	0.03	0.03	0.02	0.01
<i>ER NTP</i>	0.20	0.19	0.16	0.12	0.07	0.03	0.01	0.05	0.06	0.07	0.07	0.06	0.04	0.01
OF														
<i>RR TP</i>	0.49	0.42	0.37	0.34	0.31	0.36	0.40	0.59	0.50	0.38	0.31	0.22	0.14	0.11
<i>ER TP</i>	0.52	0.43	0.38	0.35	0.34	0.32	0.33	0.61	0.50	0.39	0.29	0.18	0.08	0.08
<i>RR NTP</i>	0.39	0.35	0.32	0.30	0.29	0.29	0.30	0.38	0.31	0.25	0.16	0.10	0.06	0.05
<i>ER NTP</i>	0.56*	0.48*	0.43*	0.40	0.39	0.39	0.38	0.64*	0.52*	0.41*	0.28	0.19	0.15	0.14
A_nR/A														
<i>RR TP</i>	0.21	0.23	0.26	0.29	0.31	0.36	0.40	0.05	0.06	0.07	0.07	0.08	0.10	0.11
<i>ER TP</i>	0.20	0.24	0.27	0.30	0.33	0.32	0.33	0.03	0.04	0.05	0.06	0.07	0.07	0.08
<i>RR NTP</i>	0.22	0.24	0.27	0.28	0.29	0.29	0.30	0.04	0.04	0.04	0.04	0.05	0.06	0.05
<i>ER NTP</i>	0.30	0.34	0.36	0.37	0.39	0.39	0.38	0.06	0.07	0.08	0.10	0.12	0.13	0.14
A_nR/R														
<i>RR TP</i>	0.47	0.36	0.28	0.21	0.12	0.04	0.02	0.59	0.50	0.38	0.31	0.20	0.10	0.04
<i>ER TP</i>	0.50	0.39	0.28	0.19	0.11	0.03	0.01	0.61	0.50	0.39	0.28	0.17	0.06	0.01
<i>RR NTP</i>	0.34	0.26	0.20	0.13	0.07	0.03	0.01	0.38	0.31	0.25	0.16	0.10	0.04	0.01
<i>ER NTP</i>	0.50	0.38	0.27	0.17	0.09	0.04	0.01	0.64*	0.52*	0.40	0.27	0.15	0.06	0.01

See the text for a description of the indices.

Highest mean values in bold (moderate to good agreement), significantly different from RR NTP (*).


respectively. Similarly, $A_{Xn}R_X/R_X$ showed only a fair overlap with values ranging between 0.3 and 0.4 for comparison of R_{40} with A_{40} , A_{50} , A_{60} , A_{70} , and A_{80} (29).

Therefore, we hypothesized that performing PETs in TP as well as using deformable registration could improve the methodology of this process and translate into better results. Our current study is the first aimed at identifying tumor areas of high risk of relapse in HNSCC using PET-CT images acquired in TP and registered with an ER method. This current work relies on 5 overlap indices with 2 registration methods on 43 HNSCC patients with local failures.

This study confirmed our first hypothesis that patient positioning remains essential, with improved overlap between LR and initial FDG tumor hotspots subvolumes in patients scanned with radiotherapy head support. In comparison to the control group (28), we noted the best agreement (moderate to good) of $OF(A_{Xn}R_{70})$ and $A_{Xn}R_{70}/R_{70}$ indices for SUVmax threshold of 30 and 40% in the TP group, ranging from 0.50 to 0.61. For example, the $OF(A_{40n}R_{70})$ and $A_{40n}R_{70}/R_{70}$ index values were 0.50 ± 0.22 in the TP group vs. 0.31 ± 0.13 in the NTP group ($p = 0.094$). Admittedly, we have only shown a trend toward significance; however, the lack of statistical power is probably due

to a small number of patients in the TP group (15 vs. 28 in the NTP group).

We have also demonstrated that using an elastic method is preferable for image registration when patients cannot be scanned in TP. The $OF(A_{Xn}R_{40})$, $OF(A_{Xn}R_{70})$, and $A_{Xn}R_{70}/R_{70}$ index values were significantly better with the ER method for SUVmax threshold of 30–50%. For instance, the $OF(A_{30n}R_{70})$ index value was good (0.64 ± 0.15) with ER vs. moderate (0.38 ± 0.14) with RR ($p = 0.014$). To our knowledge, only two other studies have been conducted using elastic image registration software. The first, conducted by Due and al. (35), on a cohort of 39 HNSCC after IMRT. However, for this study the PET baseline volumes were delineated based on visual assessment without an SUV-based semi-automated method, therefore increasing the risk of inter and intra-observer variability. Furthermore, the authors determined the overlap between subvolumes segmented on a $PET_{BASELINE}$ and a $CT_{RECURRENCEr}$, but not on a $PET_{RECURRENCE}$. Shusharina et al. prospectively studied 19 post-RT residual disease of non squamous cell lung carcinoma (NSCLC) and reported the overlap fraction of an initial sub-volume defined as the 50% SUVmax threshold and a relapse sub-volume defined as the 80% SUVmax threshold. They showed that





the obtained OF(A₅₀nR₈₀) was excellent (80%) at 2 weeks after treatment and remained good (63%) at 3 months (25).

Nevertheless, despite RT position and ER method, the hotspot on pre-RT PET-CT that is used to guide definition of areas of high risk of recurrence in patients with HNSCC remains large, and would result in a risk of error with regards to dose escalation. Indeed, the only SUVmax threshold to reach a good agreement value was 30%, which is significantly lower than the threshold obtained in previous studies conducted on other primary tumors. Aerts et al. suggested a 50% SUVmax threshold for delineation on PET_A following the OF(A₅₀nR₉₀) values higher than 70% obtained in their retrospective analysis on 22 patients with local recurrences of NSCLC (23). However, Calais et al. reported that the baseline PET subvolume defined by the 70% SUVmax threshold was an acceptable choice for dose escalation in lung cancer. This choice of threshold could prevent missing the hotspot of recurrence (A₇₀nR₉₀/R₉₀ and OF(A₇₀nR₉₀) index > 51%) and limit the irradiation of areas at low risk of relapse (A₇₀nR₄₀/A₇₀ and OF(A₇₀nR₄₀) index > 70%) (22). With this hypothesis, investigators recently assessed the feasibility of FDG PET-guided dose escalation with IMRT in 21 patients with lung cancer. With a boost to A₇₀ FDG hotspot, the mean dose to planning target volume was 72.5 ± 0.25 Gy and the dose/volume (D/V) constraints to organs at risk (OAR) were respected (36). Finally, Calais et al. reported good agreement in OF(A_XnR₄₀) for threshold of 30–60% in the 35 patients with LR of esophageal cancer. Likewise, good to excellent OF(A_XnR₉₀)

values (0.61–0.89) for threshold of 30 to 60% were reported. The authors also recommended a 60% SUVmax threshold on PET_A to delineate high FDG uptake areas on pre-RT PET/CT for a dose escalation target volume (27).

Two main hypotheses could explain why overlap index values in HNSCC are lower than in lung and esophageal cancers. Firstly, although HNSCC are frequently locally advanced at diagnosis, we noticed that MTV values were smaller in our HNSCC series (9.1 ± 7.2cc) than those reported in esophageal (25.4 ± 16.2cc) or lung (53.7 ± 45.6cc) cancers, when considering the same SUVmax threshold of 40% (22, 27). Unlike these above-mentioned tumors, head and neck cancers are known to include necrotic areas without any metabolic activity so the MTV is smaller than real tumor volume. Consequently, with smaller MTV, any mismatch during the registration process can lead to a greater overlap error. Second, weight loss and post-therapeutic tissue distortions are probably more important in HNSCC, with displacement of anatomical landmarks and rendering the registration process more difficult, even with an elastic method.

For our secondary objective, we confirmed that initial MTV and TLG on baseline PET were significantly higher in relapsed patients than locally controlled patients ($p = 0.041$ and $p = 0.046$ respectively) and appeared to be a better prognostic marker than SUVmax ($p > 0.05$). These results are also consistent with previous studies (37, 38). Mapelli et al. studied the value of MTV and TLG to predict outcomes in oropharyngeal carcinomas treated by tomotherapy with simultaneous integrated boost in



FDG-avid tumor subvolumes. They demonstrated that $MTV > 4.4cc$ and $TLG > 34.6g$ were associated with a better 3-year overall survival ($p = 0.006$ and $p = 0.01$, respectively) in a series of 41 patients (39). These results are concordant with our findings.

Textural analysis on pre-RT FDG-PET/CT, already recognized as a prognostic factor for survival (40), could be an interesting approach to predict HNSCC local recurrence sites. Beaumont et al. showed that 15 parameters extracted from a voxel to voxel analysis, combining radiomics and spatial location, allowed better prediction of local failure than a regional analysis, with a median area under the receiver-operating curve of 0.71 (41). The published literature to date mainly underlines methods in assessing tumor hypoxia, a well-known factor for RT resistance (42, 43). Thureau et al. reported that IMRT dose-painting with pre-RT 18F-misonidazole (F-MISO) PET/CT provided NSCLC radiotherapy plan matching with dose/volume (D/V) objectives and organs at risk (OAR) tolerance (36). Patients with F-MISO positive scans who received an RT boost (70 to 86Gy) tend to have a better overall survival (median 26.5 vs. 15.3 months, $p = 0.71$) (44).

Our study has some limitations. First, although larger than previous series, the number of included patients (43 LR) is relatively low, contributing to the lack of power and the inability to confirm superiority of TP when the RR method was used (28, 29). With regards to the results on the prognostic performance of the PET parameters, despite the inclusion of 199 patients, we acknowledge that the role of FDG-PET/CT in systematic follow-up to diagnose occult relapse is still not well defined, despite high performance (45, 46). Our population lacked homogeneity, with a higher proportion of patients with younger age, AJCC I-II stages, and laryngeal cancers included in the CR group. These variables are correlated with lower risk of LR (47, 48). In addition, relapse in FDG-avid lymph nodes at initial staging was not considered. It would be of interest to test the technical feasibility of this process on involved nodes, as these may also benefit for dose escalation, particularly in N3 disease. Finally, we used a PET segmentation method based on different relative SUVmax thresholds. This procedure remains a simple measurement that is easy to perform using commercially available software tools and was utilized in many studies. Van den Bogaard et al. are the only group to utilize an adaptive threshold method based on signal-to-background (26), and reported additional value compared to cancer clinical characterization alone (18, 49). However, this technique remains more tedious to implement and requires a PET calibration phase. Combinations of thresholds could lead to over- or under-estimation of overlaps, and

other PET segmentation methods, like automatic approaches should also be tested in future. In fact, several studies have suggested that the gradient-based method (50) best estimates the true tumor volume in NSCLC or HNSCC compared to the SUV-based method (51, 52). Moreover, the segmentation using the FLAB algorithm (fuzzy locally adaptive Bayesian) (53) is also an interesting model that may improve MTV delineation (54, 55). Unfortunately, this patented method is not freely available.

CONCLUSION

This study suggests that treatment position improves correlation between FDG hotspot areas on pre-RT PET/CT and sites of local relapse on post-RT PET/CT. When PET in TP is not possible, the use of an elastic registration method is significantly more accurate than a rigid registration method for overlap estimation. However, we found lower overlap index values (at best moderate to good agreement, with SUVmax thresholds of 30–50%) than those reported in other cancers. Further larger prospective studies are needed to assess other PET segmentation methods.

DATA AVAILABILITY STATEMENT

The datasets generated for this study are available on request to the corresponding author.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by CHRU Brest institutional ethic committee (n2017.CE25). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

BT, P-YS, and RA are the guarantors of the paper. BT, AC, JC, PV, P-YS, and RA designed the study. US, FL, and J-CL ensured inclusion and follow-up of patients. DB managed imaging procedures. BT, RL, PR, and RA analyzed the data. BT, DB, and RA, realized statistics. DG reviewed the English language. All authors contributed in drawing up the manuscript.

REFERENCES

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. *CA Cancer J Clin.* (2015) 65:87–108. doi: 10.3322/caac.21262
2. Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-Adjusted life-years for 32 cancer groups, 1990 to 2015: a Systematic analysis for the global burden of disease study. *JAMA Oncol.* (2017) 3:524–48. doi: 10.1001/jamaoncol.2016.5688
3. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. *Lancet Oncol.* (2010) 11:21–8. doi: 10.1016/S1470-2045(09)70311-0
4. Pignon J-P, le Maitre A, Maillard E, Bourhis J, MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. *Radiother Oncol.* (2009) 92:4–14. doi: 10.1016/j.radonc.2009.04.014

5. Tejpal G, Jaiprakash A, Susovan B, Ghosh-Laskar S, Murthy V, Budrukkar A. IMRT and iGRT in head and neck cancer: have we delivered what we promised? *Indian J Surg Oncol.* (2010) 1:166–85. doi: 10.1007/s13193-010-0030-x
6. Tobias JS, Monson K, Gupta N, Macdougall H, Glaholm J, Hutchison I, et al. Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. *Lancet Oncol.* (2010) 11:66–74. doi: 10.1016/S1470-2045(09)70306-7
7. Leeman JE, Li J-G, Pei X, Venigalla P, Zumsteg ZS, Katsoulakis E, et al. Patterns of treatment failure and postrecurrence outcomes among patients with locally advanced head and neck squamous cell carcinoma after chemoradiotherapy using modern radiation techniques. *JAMA Oncol.* (2017) 3:1487–94. doi: 10.1001/jamaoncol.2017.0973
8. Leclerc M, Maingon P, Hamoir M, Dalban C, Calais G, Nuyts S, et al. A dose escalation study with intensity modulated radiation therapy (IMRT) in t2N0, t2N1, t3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach. *Radiother Oncol.* (2013) 106:333–40. doi: 10.1016/j.radonc.2013.03.002
9. van Diessen J, De Ruyscher D, Sonke J-J, Damen E, Sikorska K, Reymen B, et al. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial). *Radiother Oncol.* (2019) 131:166–73. doi: 10.1016/j.radonc.2018.09.019
10. Welsh JW, Seyedin SN, Allen PK, Hofstetter WL, Ajani JA, Chang JY, et al. Local control and toxicity of a simultaneous integrated boost for dose escalation in locally advanced esophageal cancer: interim results from a prospective phase I/II trial. *J Thorac Oncol.* (2017) 12:375–82. doi: 10.1016/j.jtho.2016.10.013
11. Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S, et al. Three-dimensional conformal radiotherapy (3D-CRT) versus intensity modulated radiation therapy (IMRT) in squamous cell carcinoma of the head and neck: a randomized controlled trial. *Radiother Oncol.* (2012) 104:343–8. doi: 10.1016/j.radonc.2012.07.001
12. Nutting CM, Morden JB, Harrington KJ, Urbano TG, Bhide SA, Clark C, et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): a phase 3 multicentre randomised controlled trial. *Lancet Oncol.* (2011) 12:127–36. doi: 10.1016/S1470-2045(10)70290-4
13. Gupta T, Master Z, Kannan S, Agarwal JB, Ghosh-Laskar S, Rangarajan V, et al. Diagnostic performance of post-treatment fDG PET or fDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. *Eur J Nucl Med Mol Imaging.* (2011) 38:2083–95. doi: 10.1007/s00259-011-1893-y
14. Jeong J, Setton JS, Lee NY, Oh JH, Deasy JO. Estimate of the impact of fDG-avidity on the dose required for head and neck radiotherapy local control. *Radiother Oncol.* (2014) 111:340–7. doi: 10.1016/j.radonc.2014.03.018
15. Salaun P-Y, abgral R, Malard O, Querellou-Lefranc S, Quere G, Wartski M, et al. Good clinical practice recommendations for the use of PET/CT in oncology. *Eur J Nucl Med Mol Imaging.* (2020) 47:28–50. doi: 10.1007/s00259-019-04553-8
16. Steenbakkers RJHM, Duppen JC, Fitton I, Deurloo KEI, Zijp LJ, Comans EFI, et al. Reduction of observer variation using matched CT-PET for lung cancer delineation: a three-dimensional analysis. *Int J Radiat Oncol Biol Phys.* (2006) 64:435–48. doi: 10.1016/j.ijrobp.2005.06.034
17. Minn H, Sulamo S, Seppälä J. Impact of PET/CT on planning of radiotherapy in head and neck cancer. *Q J Nucl Med Mol Imaging.* (2010) 54:521–32.
18. Daisne J-F, Duprez T, Weynand B, Lonnewux M, Hamoir M, Reyckler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and fDG PET and validation with surgical specimen. *Radiology.* (2004) 233:93–100. doi: 10.1148/radiol.2331030660
19. Bhatnagar P, Subesinghe M, Patel C, Prestwich R, Scarsbrook AF. Functional imaging for radiation treatment planning, response assessment, and adaptive therapy in head and neck cancer. *Radiographics.* (2013) 33:1909–29. doi: 10.1148/rg.337125163
20. Gupta T, Kannan S, Ghosh-Laskar S, Agarwal JP. Systematic review and meta-analyses of intensity-modulated radiation therapy versus conventional two-dimensional and/or or three-dimensional radiotherapy in curative-intent management of head and neck squamous cell carcinoma. *PLoS ONE.* (2018) 13:e0200137. doi: 10.1371/journal.pone.0200137
21. Heukelom J, Hamming O, Bartelink H, Hoebbers F, Giral J, Herlestam T, et al. Adaptive and innovative radiation treatment FOR improving cancer treatment outcome (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. *BMC Cancer.* (2013) 13:84–8. doi: 10.1186/1471-2407-13-84
22. Calais J, Thureau S, Dubray B, Modzelewski R, Thiberville L, Gardin I, et al. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer. *J Nucl Med.* (2015) 56:196–203. doi: 10.2967/jnumed.114.144253
23. Aerts HJWL, van Baardwijk AAW, Petit SF, Offermann C, Loon JV, Houben R, et al. Identification of residual metabolic-active areas within individual nSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. *Radiother Oncol.* (2009) 91:386–92. doi: 10.1016/j.radonc.2009.03.006
24. Aerts HJWL, Bussink J, Oyen WJG, van Elmpt W, Folgering AM, Emans D, et al. Identification of residual metabolic-active areas within nSCLC tumours using a pre-radiotherapy fDG-PET-CT scan: a prospective validation. *Lung Cancer.* (2012) 75:73–6. doi: 10.1016/j.lungcan.2011.06.003
25. Shusharina N, Cho J, Sharp GC, Choi NC. Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy fDG PET scans in recurrent lung cancer. *Int J Radiat Oncol Biol Phys.* (2014) 89:137–44. doi: 10.1016/j.ijrobp.2014.01.047
26. van den Bogaard J, Janssen MHM, Janssens G, Buijsen J, Reniers B, Lambin P, et al. Residual metabolic tumor activity after chemo-radiotherapy is mainly located in initially high fDG uptake areas in rectal cancer. *Radiother Oncol.* (2011) 99:137–41. doi: 10.1016/j.radonc.2011.04.004
27. Calais J, Dubray B, Nkhali L, Thureau S, Lemarignier C, Modzelewski R, et al. High fDG uptake areas on pre-radiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for locally advanced oesophageal cancer. *Eur J Nucl Med Mol Imaging.* (2015) 42:858–67. doi: 10.1007/s00259-015-3004-y
28. Chaput A, Calais J, Robin P, Thureau S, Bourhis D, Modzelewski R, et al. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma. *Head Neck.* (2017) 39:1155–65. doi: 10.1002/hed.24738
29. Legot F, Tixier F, Hadzic M, Pinto-Leite T, Gallais C, Perdrisot R, et al. Use of baseline 18F-FDG PET scan to identify initial sub-volumes with local failure after concomitant radio-chemotherapy in head and neck cancer. *Oncotarget.* (2018) 9:21811–9. doi: 10.18632/oncotarget.25030
30. Pfister DG, Ang K-K, Brizel DM, Burtneess BA, Busse PM, Caudell JJ, et al. Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines. *J Natl Compr Canc Netw.* (2013) 11:917–23. doi: 10.6004/jnccn.2013.0113
31. Pukala J, Johnson PB, Shah AP, Langen KM, Bova FJ, Staton RJ, et al. Benchmarking of five commercial deformable image registration algorithms for head and neck patients. *J Appl Clin Med Phys.* (2016) 17:25–40. doi: 10.1120/jacmp.v17i3.5735
32. Thureau S, Chaumet-Riffaud P, Modzelewski R, Fernandez P, Tessonnier L, Vervueren L, et al. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3^h-deoxy-3^h-18F-fluorothymidine PET images in lung cancer. *J Nucl Med.* (2013) 54:1543–50. doi: 10.2967/jnumed.112.118083
33. Soto DE, Kessler ML, Pierr M, Eisbruch A. Correlation between pretreatment fDG-PET biological target volume and anatomical location of failure after radiation therapy for head and neck cancers. *Radiother Oncol.* (2008) 89:13–8. doi: 10.1016/j.radonc.2008.05.021
34. Troost EGC, Schinagl DAX, Bussink J, Oyen WJG, Kaanders JHAM. Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. *Radiother Oncol.* (2010) 96:328–34. doi: 10.1016/j.radonc.2010.07.017
35. Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS, et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. *Radiother Oncol.* (2014) 111:360–5. doi: 10.1016/j.radonc.2014.06.001
36. Thureau S, Dubray B, Modzelewski R, Bohn P, Hapdey S, Vincent S, et al. FDG and fMISO PET-guided dose escalation with intensity-modulated

- radiotherapy in lung cancer. *Radiat Oncol.* (2018) 13:208–7. doi: 10.1186/s13014-018-1147-2
37. Abgral R, Keromnes N, Robin P, Le Roux P-Y, Bourhis D, Palard X, et al. Prognostic value of volumetric parameters measured by 18F-FDG PET/CT in patients with head and neck squamous cell carcinoma. *Eur J Nucl Med Mol Imaging.* (2014) 41:659–67. doi: 10.1007/s00259-013-2618-1
 38. Abgral R, Valette G, Robin P, Rousset J, Keromnes N, Le Roux P-Y, et al. Prognostic evaluation of percentage variation of metabolic tumor burden calculated by dual-phase (18) FDG PET-CT imaging in patients with head and neck cancer. *Head Neck.* (2016) 38 Suppl 1:E600–. doi: 10.1002/hed.24048
 39. Mapelli P, Broggi S, Incerti E, Alongi P, Kirienko M, Fiorino C, et al. FDG-PET/CT predicts outcome in oropharyngeal carcinoma patients undergoing intensity modulated radiation therapy with dose escalation to FDG-avid tumour volumes. *Curr Radiopharm.* (2017) 10:102–10. doi: 10.2174/1874471010666170413151108
 40. Guezennec C, Robin P, Orlhac F, Bourhis D, Delcroix O, Gobel Y, et al. Prognostic value of textural indices extracted from pretherapeutic 18-F FDG-PET/CT in head and neck squamous cell carcinoma. *Head Neck.* (2019) 41:495–502. doi: 10.1002/hed.25433
 41. Beaumont J, Acosta O, Devillers A, Palard-Novello X, Chajon E, de Crevoisier R, et al. Voxel-based identification of local recurrence sub-regions from pre-treatment PET/CT for locally advanced head and neck cancers. *EJNMMI Res.* (2019) 9:90–11. doi: 10.1186/s13550-019-0556-z
 42. Lee NY, Mechalakos JG, Nehmeh S, Lin Z, Squire OD, Cai S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. *Int J Radiat Oncol Biol Phys.* (2008) 70:2–13. doi: 10.1016/j.ijrobp.2007.06.039
 43. Lee N, Nehmeh S, Schöder H, Fury M, Chan K, Ling CC, et al. Prospective trial incorporating pre-/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. *Int J Radiat Oncol Biol Phys.* (2009) 75:101–8. doi: 10.1016/j.ijrobp.2008.10.049
 44. Vera P, Mihailescu S-D, Lequesne J, Modzelewski R, Bohn P, Hapdey S, et al. Radiotherapy boost in patients with hypoxic lesions identified by 18F-FMISO PET/CT in non-small-cell lung carcinoma: can we expect a better survival outcome without toxicity? [RTEP5 long-term follow-up]. *Eur J Nucl Med Mol Imaging.* (2019) 46:1448–56. doi: 10.1007/s00259-019-04285-9
 45. Abgral R, Querellou S, Potard G, Le Roux P-Y, Le Duc-Pennec A, Marianovski R, et al. Does 18F-FDG PET/CT improve the detection of posttreatment recurrence of head and neck squamous cell carcinoma in patients negative for disease on clinical follow-up? *J Nucl Med.* (2009) 50:24–9. doi: 10.2967/jnumed.108.055806
 46. Robin P, abgral R, Valette G, Le Roux P-Y, Keromnes N, Rousset J, et al. Diagnostic performance of FDG PET/CT to detect subclinical hNSCC recurrence 6 months after the end of treatment. *Eur J Nucl Med Mol Imaging.* (2015) 42:72–8. doi: 10.1007/s00259-014-2889-1
 47. Iizuka Y, Yoshimura M, Inokuchi H, Matsuo Y, Nakamura A, Mizowaki T, et al. Recurrence patterns after postoperative radiotherapy for squamous cell carcinoma of the pharynx and larynx. *Acta Otolaryngol.* (2015) 135:96–102. doi: 10.3109/00016489.2014.949848
 48. Rosenthal DI, Mohamed ASR, Garden AS, Morrison WH, El-Naggar AK, Kamal M, et al. Final report of a prospective randomized trial to evaluate the dose-Response relationship for postoperative radiation therapy and pathologic risk groups in patients with head and neck Cancer. *Int J Radiat Oncol Biol Phys.* (2017) 98:1002–11. doi: 10.1016/j.ijrobp.2017.02.218
 49. Dibble EH, Alvarez ACL, Truong M-T, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: adding value to clinical staging. *J Nucl Med.* (2012) 53:709–15. doi: 10.2967/jnumed.111.099531
 50. Geets X, Lee JA, Bol A, Lonneux M, Grégoire V. A gradient-based method for segmenting FDG-PET images: methodology and validation. *Eur J Nucl Med Mol Imaging.* (2007) 34:1427–38. doi: 10.1007/s00259-006-0363-4
 51. Wanet M, Lee JA, Weynand B, De Bast M, Poncelet A, Lacroix V, et al. Gradient-based delineation of the primary gTV on FDG-PET in non-small cell lung cancer: a comparison with threshold-based approaches, cT and surgical specimens. *Radiother Oncol.* (2011) 98:117–25. doi: 10.1016/j.radonc.2010.10.006
 52. Castadot P, Geets X, Lee JA, Christian N, Grégoire V. Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation. *Radiother Oncol.* (2010) 95:209–17. doi: 10.1016/j.radonc.2010.03.007
 53. Hatt M, Cheze-Le-Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive bayesian segmentation approach for volume determination in PET. *IEEE Trans Med Imaging.* (2009) 28:881–93. doi: 10.1109/TMI.2008.2012036
 54. Hatt M, Visvikis D, Albarghach NM, Tixier F, Pradier O, Cheze-Le-Rest C. Prognostic value of 18F-FDG PET image-based parameters in oesophageal cancer and impact of tumour delineation methodology. *Eur J Nucl Med Mol Imaging.* (2011) 38:1191–202. doi: 10.1007/s00259-011-1755-7
 55. Hatt M, Laurent B, Fayad H, Jaouen V, Visvikis D, Le Rest CC. Tumour functional sphericity from PET images: prognostic value in nSCLC and impact of delineation method. *Eur J Nucl Med Mol Imaging.* (2018) 45:630–41. doi: 10.1007/s00259-017-3865-3

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Truffault, Bourhis, Chaput, Calais, Robin, Le Pennec, Lucia, Leclère, Gujral, Vera, Salaiün, Schick and Abgral. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.